In line with this study, House et al. identified a unique TAMs gene signature (including CXCL10 and CXCL11) that was more present in melanoma patients responding to ICB, since it was associated with a higher IFNγ gene signature [30]. The gene discussed is IFNG; the disease is melanoma.